Superior outcome of women with stage I/II cutaneous melanoma: Pooled analysis of four European organisation for research and treatment of cancer phase III trials

Journal of Clinical Oncology

Volumn 30, Issue 18, 2012, Pages 2240-2247

  Joosse, Arjen ^a   Collette, Sandra ^b   Suciu, Stefan ^b   Nijsten, Tamar ^a   Lejeune, Ferdy ^c   Kleeberg, Ulrich R ^d   Coebergh, Jan Willem W ^a   Eggermont, Alexander M M ^e   De Vries, Esther ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b EORTC DATA CENTER   (Belgium)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d Tagesklinik Struensee Haus   (Germany)

^e INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CUTANEOUS MELANOMA; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS; FEMALE; GENDER; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RECURRENCE FREE SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; SEX CHARACTERISTICS; SKIN NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84864007858     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.0584     Document Type: Article

References (47)

1. Spatz A, Batist G, Eggermont AM: The biology behind prognostic factors of cutaneous melanoma. Curr Opin Oncol 22:163-168, 2010
2. de Vries E, Bray FI, Coebergh JW, et al: Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: Rising trends in incidence and mortality but recent stabilizations in western Europe and decreases in Scandinavia. Int J Cancer 107:119-126, 2003 (Pubitemid 37100095)
3. Lasithiotakis K, Leiter U, Meier F, et al: Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer 112:1795-1804, 2008 (Pubitemid 351536840)
4. Robinson JK, Mallett KA, Turrisi R, et al: Engaging patients and their partners in preventive health behaviors: The physician factor. Arch Dermatol 145:469-473, 2009
5. Swetter SM, Johnson TM, Miller DR, et al: Melanoma in middle-aged and older men: A multiinstitutional survey study of factors related to tumor thickness. Arch Dermatol 145:397-404, 2009
6. de Vries E, Nijsten TE, Visser O, et al: Superior survival of females among 10,538 Dutch melanoma patients is independent of Breslow thickness, histologic type and tumor site. Ann Oncol 19:583-589, 2008 (Pubitemid 351325683)
7. Joosse A, De Vries E, van Eijck CH, et al: Reactive oxygen species and melanoma: An explanation for gender differences in survival? Pigment Cell Melanoma Res 23:352-364, 2010
8. Metelitsa AI, Dover DC, Smylie M, et al: A population-based study of cutaneous melanoma in Alberta, Canada (1993-2002). J Am Acad Dermatol 62:227-232, 2010
9. Rueth NM, Groth SS, Tuttle TM, et al: Conditional survival after surgical treatment of melanoma: An analysis of the Surveillance, Epidemiology, and End Results database. Ann Surg Oncol 17:1662-1668, 2010
10. Xing Y, Chang GJ, Hu CY, et al: Conditional survival estimates improve over time for patients with advanced melanoma: Results from a population-based analysis. Cancer 116:2234-2241, 2010
11. KemenyMM,Busch E, Stewart AK, et al: Superior survival of young women with malignant melanoma. Am J Surg 175:437-444, 1998; discussion 444-445
12. Joosse A, de Vries E, Eckel R, et al: Gender differences in melanoma survival: Female patients have a decreased risk of metastasis. J Invest Dermatol 131:719-726, 2011
13. Koops HS, Vaglini M, Suciu S, et al: Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: Results of a multicenter randomized phase III trial - European Organisation for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 16:2906-2912, 1998
14. Kleeberg UR, Suciu S, Bröcker EB, et al: Final results of the EORTC 18871/DKG 80-1 randomised phase III trial: rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer 40:390-402, 2004 (Pubitemid 38121277)
15. Eggermont AM, Suciu S, MacKie R, et al: Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): Randomised controlled trial. Lancet 366:1189-1196, 2005 (Pubitemid 41393597)
16. Eggermont AM, Suciu S, Rutkowski P, et al: Randomized phase III trial comparing postoperative adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation in stage II (T3-T4N0M0) melanoma: Final results of study EORTC 18961. J Clin Oncol 28:612s, 2010 (suppl; abstr 8505)
17. Akaike H: A new look at the statistical model identification. IEEE Trans Automat Contr 19:716-723, 1974
18. Balch CM, Gershenwald JE, Soong SJ, et al: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199-6206, 2009
19. Punt CJ, Buyse M, Köhne CH, et al: Endpoints in adjuvant treatment trials: A systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst 99:998-1003, 2007 (Pubitemid 47232601)
20. Coviello V, Boggess M: Cumulative incidence estimation in the presence of competing risks. Stata J 4:103-112, 2004
21. Zettersten E, Shaikh L, Ramirez R, et al: Prognostic factors in primary cutaneous melanoma. Surg Clin North Am 83:61-75, 2003 (Pubitemid 36384360)
22. Clark WH Jr, From L, Bernardino EA, et al: The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 29:705-727, 1969
23. Balch CM, Soong SJ, Gershenwald JE, et al: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622-3634, 2001 (Pubitemid 32786275)
24. Collins KK, Fields RC, Baptiste D, et al: Racial differences in survival after surgical treatment for melanoma. Ann Surg Oncol 18:2925-2936, 2011
25. Thompson JF, Soong SJ, Balch CM, et al: Prognostic significance of mitotic rate in localized primary cutaneous melanoma: An analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol 29:2199-2205, 2011
26. Tseng WH, Martinez SR: Tumor location predicts survival in cutaneous head and neck melanoma. J Surg Res 167:192-198, 2011
27. Richard MA, Grob JJ, Avril MF, et al: Melanoma and tumor thickness: Challenges of early diagnosis. Arch Dermatol 135:269-274, 1999 (Pubitemid 29159208)
28. Curtin JA, Fridlyand J, Kageshita T, et al: Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135-2147, 2005 (Pubitemid 41653105)
29. Whiteman DC, Stickley M, Watt P, et al: Anatomic site, sun exposure, and risk of cutaneous melanoma. J Clin Oncol 24:3172-3177, 2006 (Pubitemid 46638956)
30. Bauer J, Büttner P, Murali R, et al: BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res 24:345-351, 2011
31. Qi RQ, He L, Zheng S, et al: BRAF exon 15 T1799A mutation is common in melanocytic nevi, but less prevalent in cutaneous malignant melanoma, in Chinese Han. J Invest Dermatol 131:1129-1138, 2011
32. Thomas NE, Edmiston SN, Alexander A, et al: Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol Biomarkers Prev 16:991-997, 2007 (Pubitemid 46910102)
33. Kong Y, Si L, Zhu Y, et al: Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res 17:1684-1691, 2011
34. Stidham KR, Johnson JL, Seigler HF: Survival superiority of females with melanoma: A multivariate analysis of 6383 patients exploring the significance of gender in prognostic outcome. Arch Surg 129:316-324, 1994 (Pubitemid 24103326)
35. Måsbäck A, Olsson H, Westerdahl J, et al: Prognostic factors in invasive cutaneous malignant melanoma: A population-based study and review. Melanoma Res 11:435-445, 2001 (Pubitemid 32989427)
36. Micheli A, Ciampichini R, Oberaigner W, et al: The advantage of women in cancer survival: An analysis of EUROCARE-4 data. Eur J Cancer 45:1017-1027, 2009
37. Chirlaque MD, Salmerón D, Ardanaz E, et al: Cancer survival in Spain: Estimate for nine major cancers. Ann Oncol 21:iii21-iii29, 2010 (suppl 3)
38. Rutkowski P, Nowecki ZI, Zdzienicki M, et al: Cutaneous melanoma with nodal metastases in elderly people. Int J Dermatol 49:907-913, 2010
39. Gupta A, Driscoll MS: Do hormones influence melanoma? Facts and controversies. Clin Dermatol 28:287-292, 2010
40. Lens M, Bataille V: Melanoma in relation to reproductive and hormonal factors in women: Current review on controversial issues. Cancer Causes Control 19:437-442, 2008
41. de Giorgi V, Gori A, Alfaioli B, et al: Influence of sex hormones on melanoma. J Clin Oncol 29:e94-e95, 2010; author reply e96
42. Ohata C, Tadokoro T, Itami S: Expression of estrogen receptor beta in normal skin, melanocytic nevi and malignant melanomas. J Dermatol 35:215-221, 2008 (Pubitemid 351561712)
43. Morvillo V, Luthy IA, Bravo AI, et al: Androgen receptors in human melanoma cell lines IIB-MELLES and IIB-MEL-IAN and in human melanoma metastases. Melanoma Res 12:529-538, 2002 (Pubitemid 36042739)
44. Correale J, Ysrraelit MC, Gaitan MI: Gender differences in 1,25 dihydroxyvitamin D3 immunomodulatory effects in multiple sclerosis patients and healthy subjects. J Immunol 185:4948-4958, 2010
45. Field S, Newton-Bishop JA: Melanoma and vitamin D. Mol Oncol 5:197-214, 2011
46. Zbytek B, Carlson JA, Granese J, et al: Current concepts of metastasis in melanoma. Expert Rev Dermatol 3:569-585, 2008
47. Bouman A, Heineman MJ, Faas MM: Sex hormones and the immune response in humans. Hum Reprod Update 11:411-423, 2005 (Pubitemid 40895468)